JP Morgan Chase
ANIX icon

JP Morgan Chase’s Anixa Biosciences ANIX Stock Holding History

JP Morgan Chase’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.96K Buy
+2,090
New +$5.81K ﹤0.01% 7031
2024
Q1 		– Sell
-6,857
Closed -$26.6K – 7378
2023
Q4 		$26.6K Sell
6,857
-20,432
-75% -$68.9K ﹤0.01% 6182
2023
Q3 		$89.2K Hold
27,289
– – ﹤0.01% 5549
2023
Q2 		$87.3K Buy
27,289
+21,639
+383% +$83.4K ﹤0.01% 5522
2023
Q1 		$24.5K Buy
5,650
+5,000
+769% +$21.9K ﹤0.01% 5935
2022
Q4 		$3K Hold
650
– – ﹤0.01% 6236
2022
Q3 		$3K Hold
650
– – ﹤0.01% 6171
2022
Q2 		$2K Hold
650
– – ﹤0.01% 6271
2022
Q1 		$2K Hold
650
– – ﹤0.01% 6407
2021
Q4 		$2K Hold
650
– – ﹤0.01% 6493
2021
Q3 		$3K Hold
650
– – ﹤0.01% 6282
2021
Q2 		$3K Hold
650
– – ﹤0.01% 6170
2021
Q1 		$3K Sell
650
-296
-31% -$1.41K ﹤0.01% 5898
2020
Q4 		$3K Sell
946
-12
-1% -$30 ﹤0.01% 5483
2020
Q3 		$2K Hold
958
– – ﹤0.01% 5374
2020
Q2 		$3K Sell
958
-588
-38% -$1.22K ﹤0.01% 5226
2020
Q1 		$2K Hold
1,546
– – ﹤0.01% 5176
2019
Q4 		$5K Sell
1,546
-35,170
-96% -$129K ﹤0.01% 5464
2019
Q3 		$147K Buy
36,716
+28,280
+335% +$118K ﹤0.01% 4756
2019
Q2 		$29K Buy
8,436
+5,590
+196% +$23.6K ﹤0.01% 5363
2019
Q1 		$13K Buy
2,846
+1,300
+84% +$6.2K ﹤0.01% 5490
2018
Q4 		$6K Sell
1,546
-1,692
-52% -$7.27K ﹤0.01% 5508
2018
Q3 		$15K Buy
3,238
+2,342
+261% +$8.82K ﹤0.01% 5454
2018
Q2 		$3K Hold
896
– – ﹤0.01% 5451
2018
Q1 		$3K Hold
896
– – ﹤0.01% 5262
2017
Q4 		$2K Hold
896
– – ﹤0.01% 5364
2017
Q3 		$3K Hold
896
– – ﹤0.01% 4839
2017
Q2 		$1K Buy
+896
New +$1.24K ﹤0.01% 4872

Other funds holding ANIX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $5.21B AUM 31.48% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

JP Morgan Chase's ANIX Position: Q2 2026 in Review

JP Morgan Chase opened a new position in Anixa Biosciences (ANIX) in Q2 2026: 2,090 shares worth $5.96K. The stake represents ﹤0.01% of the portfolio and ranks #7031 among its holdings. This is a return to the name: JP Morgan Chase previously reported a position in ANIX as recently as Q4 2023.

JP Morgan Chase first reported a position in ANIX in Q2 2017 and has held it in 28 quarters since. The position peaked at $147K in Q3 2019. 63 funds tracked by Wall St. Rank hold ANIX as of Q2 2026.

  • JP Morgan Chase held 2,090 shares of Anixa Biosciences worth $5.96K as of Q2 2026.
  • Anixa Biosciences was a new JP Morgan Chase position in Q2 2026.
  • Anixa Biosciences made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7031 holding.
  • JP Morgan Chase first reported a position in Anixa Biosciences in Q2 2017 and has held it in 28 quarters since.
  • JP Morgan Chase's Anixa Biosciences position peaked at $147K in Q3 2019.
  • 63 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.